ADTX - Aditxt to launch first-in-human clinical trials for psoriasis therapy

Aditx Therapeutics ([[ADTX]] -3.7%) announced the upcoming launch of the first-in-human clinical trials of its therapeutic program for psoriasis.Its AditxtReprogramming therapeutics division will initiate Phase 1/2 trials Q4 2020 to evaluate the safety and efficacy of nucleic acid-based technology named Apoptotic DNA Immunotherapy™ (ADi™), the company said.Aditx has partnered with a Munich-based regulatory consultant which will work with the AditxtReprogramming team to submit an Investigational New Drug application (“IND”) to the regulatory agency in Germany."This agreement represents a major step forward as we begin advancing ADi™ for psoriasis through the regulatory process and towards the start of clinical trials,” noted company CEO Amro Albann.The company has an exclusive worldwide license for commercializing this Apoptotic DNA Immunotherapy™ (ADi™) from Loma Linda University (“LLU”).

For further details see:

Aditxt to launch first-in-human clinical trials for psoriasis therapy